Spark Therapeutics, Inc. announced earnings results for the third quarter ended September 30, 2019. For the third quarter, the company announced total revenue was USD 22.447 million compared to USD 10.707 million a year ago. Operating loss was USD 68.658 million compared to USD 51.745 million a year ago. Net loss was USD 66.602 million compared to USD 47.357 million a year ago. Basic loss per share was USD 1.72 compared to USD 1.26 a year ago. For the nine months, total revenue was USD 56.721 million compared to USD 51.568 million a year ago. Operating loss was USD 191.949 million compared to USD 135.256 million a year ago. Net loss was USD 185.190 million compared to USD 13.565 million a year ago. Basic loss per share was USD 4.82 compared to USD 0.36 a year ago.